Key Highlights
- Ionis Pharmaceuticals received FDA approval for Zanvastro to treat Alexander disease in children and adults.
- The approval was backed by Phase 1-3 results showing stabilized gait speed in patients aged five and up.
- Younger patients showed improved gross motor function, with a favorable safety profile overall.
- The drug earned a Rare Pediatric Disease Priority Review Voucher, with a U.S. launch expected within weeks.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) received FDA approval for Zanvastro to treat Alexander disease in both children and adults.
What Happened
The decision was backed by Phase 1-3 results demonstrating stabilized gait speed for patients aged five and up, alongside improved gross motor function in younger populations. The drug maintained a favorable safety profile and earned a Rare Pediatric Disease Priority Review Voucher.
Market Reaction
The disclosed information does not include stock price or trading data for Ionis Pharmaceuticals following the FDA approval.
Outlook
A domestic commercial launch of Zanvastro is slated for the next few weeks, representing the next major milestone for the newly approved therapy.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.